Friedrich-Alexander-Universitat Erlangen-Nürnberg

Edimer Pharmaceuticals, Inc.

Espoirxlhed Sarl

Neil Kirby

Pascal Schneider

Christine Kowalczyk-Quintas

Kenneth M Huttner

Holm Schneider

Anh Thu Dang

The invention relates to methods for the intra-amniotic administration of EDA agonists, in particular EDI200. Use of the methods described allow for the design of targeted therapeutic dosing and administration regimens in order to correct or alter abnormal phenotypes associated with ectodermal dysplasias, in particular, XLHED.

Intra-amniotic administration of EDI200 for the treatment of ectodermal dysplasias

The present invention relates to the preparation of substantially purified anti-EDA1 monoclonal antibodies or isolated monoclonal antibody fragments or antigen binding portions or fragments thereof as well as pharmaceutical compositions containing such antibodies. The antibodies may be used in the treatment of disorders relating to excessive action of EDA1 such as hirsutism, ectopic teeth, hyperhidrosis, breast cancer, dermal eccrine cylindroma or skin disorders such as sebaceous gland hyperplasia, comedones, milia, acne, seborrhea, rosacea, steatoma, and furuncles. The anti-EDA1 antibodies are also useful in immunoassays such as sandwich ELISA.

Anti-ectodysplasin antibodies

Growing community of inventors

Andover, MA, United States of America

Neil Kirby